Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Mayo Clinic

Sites in Rochester, MN

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 11:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1824
Shown on this page
12
Current sort
Recently updated
Campus scope
Mayo Clinic, Rochester, MN
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Mayo Clinic, Rochester, MN. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 709–720 of 1,824 matching trials with a site at Mayo Clinic, Rochester, MN.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Not applicable Interventional

Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy

NCT06055881
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Carcinoma, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Cancer
Interventions
Biospecimen Collection, Surveys, Stereotactic Body Radiation Therapy (SBRT), Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Other · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 30, 2026, 11:23 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

NCT04588922
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
SLS009, venetoclax, azacitidine
Drug
Lead sponsor
Sellas Life Sciences Group
Industry
Eligibility
12 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
19
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 30, 2026, 11:23 AM EDT
Active, not recruiting Phase 2 Interventional

Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma

NCT04069273
Site status not listed — check the official record
View directory record Official record
Conditions
Gastric Cancer, GastroEsophageal Cancer, Adenocarcinoma
Interventions
Pembrolizumab Monotherapy, Ramucirumab, Paclitaxel
Drug
Lead sponsor
Harry H Yoon
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Rochester, Minnesota • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 30, 2026, 11:23 AM EDT
Recruiting Phase 1 Interventional

Safety and Feasibility Study of the CELLSPAN Esophageal Implant (CEI) in Patients Requiring Short Segment Esophageal Replacement

NCT05877300
Status at this site: Recruiting
View directory record Official record
Conditions
Esophageal Diseases
Interventions
CEI Thoracic Surgical Implantation-Cellspan™ Esophageal Implant-Adult (CEI) in patients requiring a full reconstruction of the esophagus, CEI Extra-Thoracic Subdermal Surgical Implantation - Cellspan™ Esophageal Implant-Adult (CEI) in patients that have had a previous partial esophagectomy
Combination Product
Lead sponsor
Harvard Apparatus Regenerative Technology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
3
States / cities
Los Angeles, California • Ann Arbor, Michigan • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 30, 2026, 11:23 AM EDT
Recruiting Not applicable Interventional

Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

NCT05080673
Status at this site: Recruiting
View directory record Official record
Conditions
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Interventions
5-year and 10 Year Surveillance Colonoscopy after Qualifying Colonoscopy
Procedure
Lead sponsor
NRG Oncology
Other
Eligibility
45 Years to 70 Years
Enrollment
9,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2065
U.S. locations
478
States / cities
Fairbanks, Alaska • Goodyear, Arizona • Kingman, Arizona + 323 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 30, 2026, 11:23 AM EDT
Active, not recruiting Phase 3 Interventional

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

NCT06632327
Site status not listed — check the official record
View directory record Official record
Conditions
Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions
Surgical Procedure, Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Docetaxel, Vinorelbine, Nivolumab, Pembrolizumab, Atezolizumab, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
415
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Phoenix, Arizona + 319 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 30, 2026, 11:23 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)

NCT05506943
Site status not listed — check the official record
View directory record Official record
Conditions
Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer
Interventions
CTX-009, Paclitaxel
Drug
Lead sponsor
Compass Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
34
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 30, 2026, 11:23 AM EDT
Active, not recruiting Not applicable Interventional Results available

Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms

NCT03728985
Site status not listed — check the official record
View directory record Official record
Conditions
Thoracoabdominal Aortic Aneurysm
Interventions
GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
19 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
42
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 30, 2026, 11:23 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk

NCT06557057
Status at this site: Recruiting
View directory record Official record
Conditions
HER2-Positive Breast Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
Female only
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 30, 2026, 11:23 AM EDT
Recruiting Phase 1 Interventional

A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

NCT07027514
Status at this site: Recruiting
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
tolododekin alfa, Cetrelimab
Drug
Lead sponsor
Ankyra Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
11
States / cities
Coral Gables, Florida • Jacksonville, Florida • Peoria, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 30, 2026, 11:23 AM EDT
Recruiting Phase 1 Interventional

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

NCT05245500
Status at this site: Recruiting
View directory record Official record
Conditions
Mesothelioma, Non Small Cell Lung Cancer, Malignant Peripheral Nerve Sheath Tumors, Solid Tumor, Pancreatic Adenocarcinoma, Advanced Solid Tumor
Interventions
MRTX1719
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
24
States / cities
Phoenix, Arizona • Lone Tree, Colorado • Jacksonville, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 30, 2026, 11:23 AM EDT
Recruiting Phase 2Phase 3 Interventional

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

NCT05174169
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Stage III Colon Cancer
Interventions
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
Device · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
1,912 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1037
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 723 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 30, 2026, 11:23 AM EDT

About this Mayo Clinic institution page

What this page lists
ClinicalTrials.gov records that list Mayo Clinic in Rochester, MN as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Mayo Clinic at any site, browse by condition, or browse by U.S. city.